An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis

This study has been completed.

Study NCT00402688 Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

First Received: November 21, 2006 Last Updated: July 21, 2009 History of Changes

Study Type:	Interventional
Study Design:	Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment
Condition:	Prostatitis
Intervention:	Drug: levofloxacin

Participant Flow

Show Participant Flow

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Levofloxacin 750mg for 2 Weeks	levofloxacin, 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
Levofloxacin 750mg for 3 Weeks	levofloxacin, 750mg tablet once daily for 3 weeks followed by 1 week of placebo.
Levofloxacin 500mg for 4 Weeks	levofloxacin, 500mg tablet once daily for 4 weeks.

Baseline Measures

	Levofloxacin 750mg for 2 Weeks	Levofloxacin 750mg for 3 Weeks	Levofloxacin 500mg for 4 Weeks	Total
Number of Participants [units: participants]	81	81	80	242
Age [units: participants]
<=18 years	0	0	0	0
Between 18 and 65 years	65	71	65	201
>=65 years	16	10	15	41
Gender [units: participants]
Female	0	0	0	0
Male	81	81	80	242

Outcome Measures

Show All Outcome Measures

1. Primary:

Clinical Success [ Posttherapy Visit (Study Day 33-36) ]

Show Outcome Measure 1

2. Secondary:

Symptom Relief (Resolved) [ Posttherapy Visit (Study Day 33-36) ]

Show Outcome Measure 2

3. Secondary:

Clinical Success (Non-Relapse) or Failure (Relapse) [ Poststudy Telephone contact at 6 weeks ]

Show Outcome Measure 3

4. Secondary:

Clinical Success (Non-Relapse) or Failure (Relapse) [ Poststudy Telephone contact at 3 Months ]

Show Outcome Measure 4

5. Secondary:

Clinical Success (Non-Relapse) or Failure (Relapse) [ Poststudy Telephone Contact at 6 Months ]

Show Outcome Measure 5

6. Secondary:

Total NIH-CPSI Score [ Screening/Admission, On-Therapy, Week 3, Week 4, Posttherapy (Study Day 33-36) ]

Show Outcome Measure 6

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Therapeutic Area Lead, Anti-Infective Franchise
Organization: Ortho-McNeil Janssen Scientific Affairs, LLC
phone: 908-927-5220

No publications provided

Responsible Party:	Ortho McNeil Janssen Scientific Affairs, LLC ( VP Medical Affairs )
Study ID Numbers:	CR012103
Study First Received:	November 21, 2006
Results First Received:	March 20, 2009
Last Updated:	July 21, 2009
ClinicalTrials.gov Identifier:	NCT00402688 History of Changes
Health Authority:	United States: Food and Drug Administration